24 Sep 2021 11:10
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GSK, AstraZeneca and J&J join forces with universities for tech transfer fund
Mon, 25th Jan 2016 15:21
(ShareCast News) - AstraZeneca, GlaxoSmithKline and Johnson & Johnson and three leading UK universities are joining forces to try to significantly improve the speed that academic scientific research is translated into new medicines.The University of Cambridge, Imperial College London and University College London, via their technology transfer units, which include AIM-listed Imperial Innovations, have teamed up with the three big pharma companies to create the Apollo Therapeutics Fund.The university tech transfer units will each pay £3.3m over the life of the fund and the corporates adding £10m each to create the £40m Apollo fund.Apollo aims to combine the skills of the university academics with industry expertise at an early stage with the aim of speeding up the development of new medicines, as well as reducing the cost and improving the attrition rate of potential opportunities, while sharing the risk of early development.The fund will bring academic preclinical research to the stage of development at which either GSK, Astra or J&J will negotiate for the rights or they can be out-licensed.Apollo's investment committee will be chaired by Ian Tomlinson, GSK's former senior vice president for worldwide business development and biopharmaceuticals R&D.Russ Cummings, chief executive of Imperial Innovations, said the company's active participation in Apollo "will increase the funds that can be deployed to support the outstanding research emanating from these three world-class universities, as well as strengthening our existing relationships with the three world-leading global pharma companies."Crucially, having the pharma partners in Apollo involved right from the start ensures that projects will be selected and shaped at a very early stage to maximise the chances of commercial success."
More News
5 Jan 2017 16:45
Imperial Innovations completes quick-change to Touchstone
(ShareCast News) - Imperial Innovations Group announced on Thursday that, further to the shareholder approval received at its AGM on 21 November 2016, the change of the company's name to Touchstone Innovations took effect on 4 January. The AIM-traded firm added that, with effect from 0800 GMT on Thu
Read more28 Oct 2016 14:18
Imperial Innovations to change name to 'Touchstone'
(ShareCast News) - Imperial Innovations Group announced on Friday that at its annual general meeting on 21 November, it will be seeking shareholder approval to change the name of the company to Touchstone Innovations. The AIM-traded group was originally formed as the technology transfer office for I
Read more24 Oct 2016 15:04
Imperial Innovations celebrates investment momentum
(ShareCast News) - Imperial Innovations Group noted on Monday that its portfolio company, Veryan Medical, has completed enrolment into the MIMICS-2 clinical study of its BioMimics 3D Self-Expanding Stent System. The AIM-traded firm said the MIMICS-2 study is a prospective, multicentre, interventiona
Read more13 Oct 2016 08:36
Imperial Innovations' increases investments as pre-tax loss widens
(ShareCast News) - Imperial Innovations' annual pre-tax loss widened while the technology commercialisation and investment company increased investments across its business with universities and a joint venture. For the year ended 31 July, the pre-tax loss widened to £63.1m from £15.1m, last year, w
Read more6 Oct 2016 15:15
6 Oct 2016 15:15
Imperial Innovations shares up on portfolio company progress
(ShareCast News) - Imperial Innovations Group updated the market on Thursday, noting that its portfolio company TopiVert Pharma has announced that the first patients have been dosed in its Phase IIa proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of T
Read more3 Oct 2016 15:20
Imperial Innovations sells Permasense portfolio business
(ShareCast News) - AIM-listed Imperial Innovations has sold its portfolio company Permasense to Fortune 500 company Emerson Electric for an initial consideration of £30.6m in cash. Further amounts of up to £10m may be paid in addition, subject to the Permasense business achieving certain performance
Read more21 Sep 2016 12:23
Imperial Innovations invests £5.1m in new biotech start-up
(ShareCast News) - AIM-listed technology investor Imperial Innovations invested £5.1m in Artios Pharma, a new biotech start-up launched on Wednesday. Imperial Innovations contributed £5.1m to the £25m series A funding round, giving it a 14.9% interest in the new Cambridge- based company. Artios, wh
Read more19 Aug 2016 09:23
Cambridge University innovation investor raises 75 million pounds
LONDON, Aug 19 (Reuters) - Cambridge Innovation Capital, which commercializes technology and healthcare research from Cambridge University, has raised 75 million pounds ($98 million) from investors, including for the first time Woodford Investment Management. CIC, founded in 2013, has alrea
Read more